论文部分内容阅读
目的研究手术联合腹腔或盆腔热灌注化疗的安全性、毒副作用、并发症和抗癌疗效。方法进展期胃肠癌患者 5 0例 ,随机分为热灌注化疗组和非热灌注化疗组 ,观察热灌注化疗期间生命体征 ,术后毒副作用、并发症 ;比较两组患者的术后复发和生存率。结果热灌注化疗期间患者生命体征无明显变化 ,术后无明显的毒副作用和并发症出现。两组 3年死亡率差异无显著意义 (χ2 =3 38,P >0 0 5 ) ,但两组术前病变已浸透浆膜或 /和已有腹腔内转移者比较 ,2年时病死率 (χ2 =3 85 ,P <0 0 5 ) ,3年时病死率 (χ2 =4 6 4,P <0 0 5 )和 2年时复发率 (χ2 =4 30 ,P <0 0 5 ) ,3年时复发率(χ2 =4 15 ,P <0 0 5 )复发率差异均有显著意义。结论手术联合腹腔或盆腔热灌注化疗是防治进展期胃肠癌术后腹腔局部或区域复发 ,提高生存率较有效的辅助治疗方法。
Objective To investigate the safety, side effects, complications and anti-cancer efficacy of surgery combined with intraperitoneal or pelvic hyperthermic perfusion chemotherapy. Methods A total of 50 patients with advanced gastrointestinal cancer were randomly divided into thermal infusion chemotherapy group and non-thermal infusion chemotherapy group. Vital signs, postoperative toxicities and complications after thermal infusion chemotherapy were observed. Postoperative recurrence was compared between the two groups. Survival rate. Results There was no significant change in the patient’s vital signs during the thermal infusion chemotherapy. There were no obvious toxic side effects and complications after the operation. There was no significant difference in the three-year mortality rate between the two groups (χ2 = 3 38, P > 0 05), but the preoperative lesions in the two groups had been immersed in serosa or compared with those who had already had intra-abdominal metastases. Mortality at 2 years ( Χ2 = 3 85, P <0 0 5 ), Mortality at 3 years (χ 2 = 4 6 4, P <0 05) and Relapse rate at 2 years (χ 2 = 4 30, P <0 0 5), 3 The recurrence rate (χ2 = 4 15 , P <0 05) of the relapse rate at the time of year was significantly different. Conclusions Surgery combined with intraperitoneal or pelvic hyperthermic perfusion chemotherapy is an effective adjuvant therapy to prevent local or regional recurrence of abdominal cavity after advanced gastrointestinal cancer and improve survival.